SPHDF Revenue

In the year 2024, Santhera Pharmaceuticals Holding AG had annual revenue of 39.12M CHF, down -62.17%. Santhera Pharmaceuticals Holding AG had revenue of 25.00M in the half year ending December 31, 2024, with 1,944.40% growth.

Revenue

39.12M CHF

Revenue Growth

-62.17%

P/S Ratio

4.57

Revenue / Employee

498.31K CHF

Employees

Market Cap

197.15M USD

Revenue Chart

* This company reports financials in CHF.

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	39.12M	-64.30M	-62.17%
Dec 31, 2023	103.41M	95.94M	1,283.84%
Dec 31, 2022	7.47M	9.07M	-568.53%
Dec 31, 2021	-1.60M	-16.60M	-110.63%
Dec 31, 2020	15.01M	-60.37M	-80.09%
Dec 31, 2019	Pro	Pro	Pro
Dec 31, 2018	Pro	Pro	Pro
Dec 31, 2017	Pro	Pro	Pro
Dec 31, 2016	Pro	Pro	Pro
Dec 31, 2015	Pro	Pro	Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name	Revenue
Endo, Inc.	1.73B
Veradigm	588.02M
Tian'an Technology Group	1.78M
Elite Pharmaceuticals	84.04M
Glass House Brands	215.62M
American Oncology Network	1.76B
Northwest Biotherapeutics	1.47M
Silence Therapeutics	27.70M

Revenue Rankings

Santhera Pharmaceuticals Holding AG News

2 months ago - Santhera Pharmaceuticals reports FY results - Seeking Alpha
6 months ago - Santhera Pharmaceuticals Provides Update on Royalty Agreement for AGAMREE® (Vamorolone) and Warrants held by Idorsia - GlobeNewsWire
6 months ago - Santhera Enters into Supply and Distribution Agreement for AGAMREE® (Vamorolone) with Clinigen Group - GlobeNewsWire
10 months ago - Santhera Enters into an Exclusive Distribution Agreement with GENESIS Pharma for AGAMREE® (Vamorolone) in Central and Eastern Europe - GlobeNewsWire

More News